Cingulate Inc. Common Stock CING · Stock Open Cingulate Inc. Common Stock in new tab
Cingulate Inc. Common Stock Analysis (CING)
Is Cingulate Inc. Common Stock a good investment? Cingulate Inc. Common Stock (CING) is currently trading at 5.23 USD. Market analysts have a consensus price target of 21.20 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.03. This relatively low multiple may signal that Cingulate Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Cingulate Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.88.
Investor FAQ
Does Cingulate Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cingulate Inc. Common Stock?
Cingulate Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -3.56.
Company Profile
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 30, 2023 | 1:20 |
| Aug. 9, 2024 | 0.08 |
Community Discussion